Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

ATB200-02: Phase I/II

Treating: Pompe Disease

Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III

Treating: Axial Spondyloarthritis

Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CAIN457K2340: Phase III

Treating: Axial Spondyloarthritis

Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis

D169CC00001 (Deliver-HF): Phase III

Treating: Heart Failure

Status: Open/Currently enrolling
An international, double-blind, randomized, placebo-controlled phase III study to evaluate the effect of Dapagliflozin on reducing CV death or worsening heart failure in patient with heart failure with preserved ejection fraction (HFpEF)

EFC14828 (Amplitude-O): Phase III

Treating: Diabetes

Status: Open/Currently enrolling
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk

IDR-OM-02: Phase III

Treating: Oral Mucositis

Indication: Squamous Cell Carcinoma (head/neck cancers)
Status: Open/Currently Enrolling
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Meet Our Providers

Brandon McCafferty, MD


Optical Center

Vision Center

Antonio Santin, MD, FACS


Plastic Surgery

Kenneth D. Evans, AuD



Andrew Blackman, MD

Orthopedic Destination Center

Orthopedics / Orthopaedics

Russell Herring, DNP

Family Practice